Expert Insights Into the Biosafety of Oncolytic Immunotherapies and Their Combination With Immune Checkpoint Inhibitors

Do you know how the biosafety risks of oncolytic immunotherapies and their combination with immune checkpoint inhibitors can be mitigated?

Credit available for this activity expires: 6/22/24 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/993479?ecd=bdc_podcast_libsyn_mscpedu